BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 10, 2018
View Archived Issues
FDA grants orphan drug designation to tenalisib for treatment of cutaneous T-cell lymphoma
Read More
Allogene Therapeutics finalizes CAR T therapy asset transaction with Pfizer
Read More
Novel DEC cell therapy demonstrates efficacy in mouse model of Duchenne muscular dystrophy
Read More
Ionis licenses drug candidate for NASH to AstraZeneca
Read More
Gruenenthal enters nonopioid drug collaboration with KU Leuven
Read More
ALT-803/nivolumab combination shows antitumor activity in non-small cell lung cancer study
Read More
Novel miRNAs found upregulated in schizophrenia
Read More
Oncology Venture Sweden agrees to inlicense dovitinib from Novartis
Read More
DMC recommends continuation of phase III OPTIMA study of ThermoDox
Read More
Bayer presents novel muscarinic M2 receptor positive allosteric modulators
Read More
Topline data presented from phase IIa study of THX-110 in Tourette syndrome
Read More
Novel bromodomain inhibitors identified at the University of Michigan
Read More
Janssen describes novel menin-MLL interaction inhibitors
Read More
Primary endpoint met in phase III KEYNOTE-042 study
Read More
AstraZeneca discovers new phosphatidylinositol 3-kinase inhibitors
Read More
RegeneRx announces outcome of FDA discussions regarding the development of RGN-259
Read More
BeiGene identifies new IDO-1/TDO inhibitors
Read More
RP-5063 granted FDA orphan drug designation for the treatment of idiopathic pulmonary fibrosis
Read More
STEADFAST phase IIIa study of azeliragon does not meet coprimary efficacy endpoints
Read More
Additional data presented from phase II trial of brilacidin-OM in severe oral mucositis
Read More
SELECT-COMPARE phase III study meets all primary and ranked secondary endpoints
Read More
Intra-Cellular Therapies presents further data on ITI-007 for schizophrenia
Read More
FDA grants orphan drug designation for elamipretide for treatment of Barth syndrome
Read More